AstraZeneca pays insitro $40m upfront for AI target discovery in MASH and heart disease

AstraZeneca agreed on 15 October 2026 to pay insitro $40 million upfront for AI-led target discovery in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies, with up to about $1.46 billion more tied to development and commercial milestones¹. Fierce Biotech values the whole agreement at $1.5 billion².

What the deal covers

insitro will run its Virtual Human platform, which combines large-scale human and cellular data with AI-based target identification and medicine design, to find the causal biology behind both diseases¹. The company will then take targets that AstraZeneca nominates from discovery to the development candidate stage¹. AstraZeneca takes over from there, using its clinical development and regulatory teams, and holds exclusive worldwide rights to the programmes it selects¹.

On top of the upfront payment and milestones, insitro can earn single digit royalties on global sales of any resulting medicines¹. Sharon Barr, who heads BioPharmaceuticals R&D at AstraZeneca, described target selection as "one of the most critical decisions in R&D"¹. Daphne Koller, insitro's founder and chief executive, called MASH and cardiomyopathies "prevalent, underdiagnosed diseases where high-content data holds immense signal for uncovering disease drivers"¹.

What it means for the market

The deal adds AstraZeneca to a growing list of large drugmakers paying for insitro's platform. Gilead signed in 2019 and Bristol Myers Squibb in 2020, a deal BMS has since extended and expanded, while Eli Lilly joined in 2024². For an AI-first discovery company, repeat platform deals with big pharma are a source of non-dilutive capital: Fierce Biotech notes that insitro has used these pacts to fund its own early-stage pipeline in liver fat and fibrosis, obesity, neuroscience and ophthalmology, having last raised $400 million in 2021².

For AstraZeneca, the agreement is one more step in a wider build-out of AI capability. Fierce Biotech lists a target discovery partnership with Algen Biotechnologies in immunology, the acquisition of Modella AI and an agentic AI licensing deal with Owkin alongside the company's internal investment². Cardiovascular, renal and metabolism is one of AstraZeneca's main disease areas and, in the company's words, "a key growth driver"¹.

The structure is the market signal for investors. The guaranteed part is the $40 million upfront, against up to about $1.46 billion in milestones, and Fierce Biotech describes the financial terms of insitro's pharma deals as back loaded¹². The bulk of the money depends on targets turning into development candidates and then into medicines that reach the market. For other AI target discovery vendors, the deal sets a reference point: a modest guaranteed payment, a milestone package in the billion-dollar range and single digit royalties, with the pharma partner keeping worldwide rights¹.

Caveats

The collaboration starts at target discovery, so no clinical programme yet exists under it, and neither company has given a timeline for the first development candidate¹. The headline $1.5 billion figure is mostly potential milestone payments rather than committed cash². Which programmes advance is AstraZeneca's choice, since it holds the rights to select them¹.